# Revagenix

**Canonical:** https://apis.io/providers/revagenix/  
**Website:** https://www.revagenix.com/  
**APIs profiled:** 0

Revagenix, Inc. is a private clinical-stage precision-therapeutics company headquartered in San Francisco, California, founded in 2019 by antibacterial-discovery veterans from Achaogen. The company takes a first-principles approach to drug design for serious chronic disease, engineering each candidate around target biology, route of delivery and tolerability. Its lead program, Rev-56, is a first-in-class inhaled precision therapy with a novel mechanism of action targeting chronic Pseudomonas infection in non-cystic-fibrosis bronchiectasis (NCFB), a progressive respiratory disease affecting an estimated 350,000 to 500,000 adults in the United States; Rev-56 is entering Phase 1 clinical development in 2026, with a dry-powder formulation approaching candidate selection. Revagenix is backed by Novo Holdings, Tenmile, the REPAIR Impact Fund and the National Institute of Allergy and Infectious Diseases (NIAID contract 75N93022C00061). Revagenix is a therapeutics developer, not a software vendor: it publishes no API, SDK, developer portal or machine-readable contract.

## Kin Score — 5.5 / 100 (minimal)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 5.5).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 7.1 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Revagenix Domain Security** — TLSv1.3 · HSTS

## Tags

Company, Biotechnology, Pharmaceuticals, Life Sciences, Therapeutics, Anti-Infectives, Respiratory, Clinical Stage, Drug Discovery, Private Company

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/revagenix/). Scores are computed from the provider's own public artifacts under a published rubric.